อ้างอิงข้อมูลจาก 1. Allergan Aesthetics. HArmonyCa™ Lidocaine IFU August 2023 2. Urdiales-Gálvez F et al. J Cosmet Dermatol. 2023;00:1-12

ผลลัพธ์ที่ได้ขึ้นกับแต่ละบุคคลและความชำนาญของแพทย์ผู้ทำการรักษา สามารถสอบถามข้อมูลเพิ่มเติมได้ที่บุคลากรการแพทย์ ผลิตภัณฑ์ให้ใช้โดยผู้ประกอบวิชาชีพเวชกรรมเท่านั้น

CONTRA-INDICATIONS: Do not inject HArmonyCa™ Lidocaine in patients with a known sensitivity to any of the product components, suffering from skin disease or abnormal skin conditions, suffering from an infection or inflammation (either acute or chronic) at or near the treatment site, patients susceptible to keloid formation, hypertrophic scarring, or developing inflammatory skin conditions, patients with impaired wound healing due to systemic disorders, medicinal drugs, or unhealthy or poorly-vascularized tissue, suffering from prolonged bleeding or tissue healing due to medical conditions or medicinal drugs, patients with a history of anaphylactic reactions and/or multiple severe allergies, patients with a known sensitivity to steroids, or who are contraindicated to be treated with steroids. Do not inject into glabellar or periocular areas, lips and perioral region, and regions containing foreign bodies. Do not inject into blood vessels and highly vascularized areas, epidermis, or superficial dermis. Patients who are presenting with herpes, autoimmune diseases, are breastfeeding or pregnant women, are below the age of 18, have known hypersensitivity to lidocaine or to other amide-type local anesthetics, and with conditions for which lidocaine is contraindicated.